Search Results
Your search for ,WhO matches 21057 pages
Showing 12551 - 12600New Persistent Opioid Use After Curative-Intent Cancer Surgery
A study reported by Lee et al in the Journal of Clinical Oncology indicates that approximately 10% of patients undergoing curative-intent surgery for cancer become new persistent opioid users. Study Details The study involved data from 68,463 patients from a national data set of insurance claims...
The Liver Meeting: Daily Aspirin May Reduce Risk for Hepatitis B Virus–Related Liver Cancer
A new study presented at The Liver Meeting, held by the American Association for the Study of Liver Diseases, found that daily aspirin therapy was significantly associated with a reduced risk in hepatitis B virus (HBV)–related liver cancer (Abstract 223). According to AASLD’s...
The Liver Meeting: Direct-Acting Antiviral Medications as Hepatitis C Treatment May Reduce Risk of Liver Cancer
A new study presented at The Liver Meeting—held by the American Association for the Study of Liver Diseases—found that eradication of the hepatitis C virus induced by direct-acting antiviral medications is associated with a 71% reduction in the risk of liver cancer (Abstract 142)....
Long-Term Survivors of Childhood Cancer Prone to ‘Job Lock’ due to Worries About Losing Health Insurance
The results of a national cancer survey reveal a significant number of childhood cancer survivors are worried about keeping their health insurance, to the point of letting it affect their career decisions. The findings were published by Kirchhoff et al in JAMA Oncology. Anne Kirchhoff, PhD,...
HSD3B1 Genotype and Outcomes With ADT After Radiotherapy for Localized Prostate Cancer
In a study reported in JAMA Oncology, Hearn et al found that the presence of the HSD3B1 (1245C) allele was associated with more rapid development of metastases in patients receiving androgen-deprivation therapy for biochemical recurrence after primary radiation therapy for localized prostate...
ASCO/CCO Focused Guideline Update on Role of Bone-Modifying Agents in Metastatic Breast Cancer
As reported by Catherine Van Poznak, MD, of the University of Michigan, Ann Arbor, and colleagues in the Journal of Clinical Oncology, ASCO and Cancer Care Ontario (CCO) have collaborated in providing a focused update for the ASCO clinical practice guideline on the role of bone-modifying agents in...
ASHG 2017: Quantifying Breast Cancer Risk Based on Rare Variants and Background Risk
Rare variants combined with background genetic risk factors may account for many unexplained cases of familial breast cancer, and knowing the specific genes involved could inform choice of prevention and treatment strategies, according to findings presented in a plenary session at the American...
FDA Approves New Treatment for Adults With Mantle Cell Lymphoma
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to acalabrutinib (Calquence) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy. “Mantle cell lymphoma is a particularly aggressive cancer,” said Richard...
AACR-NCI-EORTC: NCI-MATCH Reaches Central Patient-Screening Goal
The National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) clinical trial has achieved the goal of screening nearly 6,000 patients in just under 2 years, according to data presented by Chen et al at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer...
AACR-NCI-EORTC: Noninvasive Computational Imaging Approach May Help Predict Response to Immunotherapy
A computational imaging-based signature of immune-cell infiltration in and around a tumor could predict patients’ responses to treatment with anti–programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) immunotherapies, according to data from a study presented by Sun et...
AACR-NCI-EORTC: Tipifarnib Shows Durable Antitumor Activity in HRAS-Mutant Head and Neck Cancer
Preliminary results from a phase II open-label trial of tipifarnib, a farnesyltransferase inhibitor, in patients with HRAS-mutant head and neck squamous cell carcinoma (HNSCC) were presented by Alan L. Ho, MD, PhD, of Memorial Sloan Kettering Cancer Center, at the AACR-NCI-EORTC International...
AACR-NCI-EORTC: Gene Therapy Shows Early Efficacy Against Recurrent Brain Cancer
More than a quarter of patients with recurrent high-grade glioma treated with the retroviral vector Toca 511 (vocimagene amiretrorepvec) combined with Toca FC (an extended-release formulation of fluorocytosine, a prodrug of fluorouracil [5-FU]) were alive more than 3 years after...
2-Year Survival Outcomes With Immunotherapy in Advanced NSCLC
Analysis of 2-year overall survival with nivolumab (Opdivo) vs docetaxel in the phase III CheckMate 017 and 057 trials showed a continued survival benefit with nivolumab in patients with previously treated advanced non–small cell lung cancer (NSCLC). The findings were reported by Horn et al...
Potential Risk Activities and Breast Cancer–Related Lymphedema in Patients Undergoing Bilateral Surgery
In a study reported in the Journal of Clinical Oncology, Asdourian et al found that several factors considered to pose an increased risk of lymphedema were not significantly associated with the occurrence of lymphedema among women undergoing bilateral breast cancer surgery. Study Details In the...
FDA Accepts sBLA for Nivolumab in Resected, High-Risk, Advanced Melanoma
On October 16, Bristol-Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application (sBLA) for nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete...
FDA Approves Intravenous Rolapitant for Delayed Chemotherapy-Induced Nausea and Vomiting
On October 25, the U.S. Food and Drug Administration (FDA) approved intravenous (IV) rolapitant (Varubi) in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including,...
CELESTIAL Trial: Cabozantinib Meets Primary Endpoint of Overall Survival in Patients With Advanced Hepatocellular Carcinoma
On October 16, Exelixis announced that its global phase III CELESTIAL trial met its primary endpoint of overall survival, with cabozantinib (Cabometyx) providing a statistically significant and clinically meaningful improvement in median overall survival compared to placebo in patients with...
Potential Treatment of Chordoma With PI3K Inhibitors
Patients with chordoma—a rare bone cancer of the skull and spine—could be helped by existing treatments, suggest scientists from the Wellcome Trust Sanger Institute, University College London Cancer Institute, and the Royal National Orthopaedic Hospital NHS Trust. In the largest...
Changes in Opioid Prescription for Cancer Patients Referred to Outpatient Palliative Care
In a study reported in the Journal of Oncology Practice, Haider et al found that the median morphine equivalent daily dose decreased significantly among cancer patients seen at MD Anderson Cancer Center’s outpatient palliative care clinic between 2010 and 2015. Use of hydrocodone decreased...
Anti–T-Lymphocyte Globulin and Chronic GVHD-Free Survival in Unrelated Myeloablative HCT
A double-blind phase III trial has shown no benefit of anti–T-lymphocyte globulin (ATLG) vs placebo on chronic graft-vs-host disease (GVHD)-free survival in patients undergoing human leukocyte antigen (HLA)-matched unrelated myeloablative hematopoietic cell transplantation (HCT). The study...
FDA Grants Priority Review for Olaparib in Metastatic Breast Cancer
On October 18, AstraZeneca and Merck & Co announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a supplemental New Drug Application (sNDA) for the use of olaparib (Lynparza) tablets in patients with germline BRCA-mutated, HER2-negative...
2017 ASCO Palliative Care: Yoga Can Be an Effective Supportive Therapy for People With Lung Cancer and Their Caregivers
In a feasibility trial of people with advanced lung cancer receiving radiation therapy and their caregivers, yoga was beneficial to both parties. These findings will be presented by Milbury et al at the upcoming 2017 Palliative and Supportive Care in Oncology Symposium in San Diego (Abstract 125). ...
2017 ASCO Palliative Care: People With Leukemia and Their Oncologists Have Vastly Different Perceptions of Prognosis
A study of 100 people with acute myeloid leukemia (AML) receiving chemotherapy found that patient and physician perceptions of treatment risk and the likelihood of a cure varied widely. Overall, patients tended to overestimate both the risk of dying due to treatment and the likelihood of a cure....
MAF Amplification and Outcomes With Adjuvant Zoledronic Acid in Early Breast Cancer
An analysis from the phase III AZURE trial has shown that MAF-negative status was associated with a benefit and MAF-positive status, with a detriment of adjuvant zoledronic acid in early breast cancer. The analysis was reported by Coleman et al in The Lancet Oncology. Study Details The current...
Long-Term Outcomes With BRAF and MEK Inhibition in BRAF V600–Mutant Metastatic Melanoma
As reported by Long et al in the Journal of Clinical Oncology, a 5-year landmark analysis of patients receiving dabrafenib (Tafinlar) and trametinib (Mekinist) for BRAF V600–mutant metastatic melanoma shows persistent overall and progression-free survival benefits. Study Details The...
Moffitt Cancer Center Holds Leadership Series in New York
Moffitt Cancer Center has made a lasting commitment to the prevention and cure of cancer, working fervently in the areas of patient care, research, and education to advance further in fighting this disease, according to Alan F. List, MD, Moffitt’s President and Chief Executive Officer. Dr. List,...
Leading Lymphoma Clinician, Researcher, and Mentor, Oliver ‘Ollie’ Press, MD, PhD, Dies at 65
In 1988, 38-year-old Rita Lawrence found herself in a desperate situation. The lymphoma she’d been battling had recurred after 2 years of remission. She’d endured multiple rounds of tough chemotherapy, but it couldn’t stave off the swiftly growing tumors. When she learned of a radioimmunotherapy...
BE PREPARED TO ENCOURAGE HPV VACCINATION
“Human papillomavirus (HPV) vaccination coverage lags behind coverage for the other vaccines recommended for preteens,” according to the Centers for Disease Control and Prevention (CDC).1 A recent report about vaccination coverage in the United States among adolescents aged 13 to 17 found that...
2017 ASCO Palliative Care: Resilience Intervention Improves Quality of Life for Adolescents and Young Adults With Cancer
Although a cancer diagnosis is daunting at any age, adolescents and young adults (AYAs) with the disease often face unique challenges and are at risk for poor psychosocial outcomes than older patients. A randomized study investigating whether a brief, age-appropriate, skills-based intervention...
2017 ASCO Palliative Care: Patients With Advanced Cancer Prefer Oncologists Not Use Computers in the Exam Room
Although the use of electronic health records in oncology care has led to improved care for patients, results from a new study show that oncologists need to be cautious about using computers during exam room visits, especially for patients with advanced cancer. The randomized study compared...
Register for December 1 FDA Workshop on Cardiovascular Toxicities in Immunotherapy Trials
THE U.S. FOOD & DRUG ADMINISTRATION (FDA) and the Oncology Center of Excellence (OCE) will host a complimentary public workshop, Assessment of Cardiovascular Toxicities in Immuno-Oncology Trials, on December 1. ASCO is supporting the workshop with the American College of Cardiology (ACC), the...
Recommend an Early-Career Oncologist for ASCO’s 2018 Health Policy Fellowship
APPLICATIONS ARE now being accepted for ASCO’s 2018 Health Policy Fellowship program. The Health Policy Fellowship aims to provide oncology fellows and early-career physicians with the necessary skills to shape cancer policy and to help increase the involvement of ASCO members in policy, advocacy,...
Documentary Film Takes a Walk on the Wild Side With Oncology Pioneers
Oncology luminaries. Thought leaders. The soul of chemotherapy. These are just a few of the phrases used to describe Emil Frei, MD, FASCO, Emil J Freireich, MD, FASCO, James F. Holland, MD, FASCO, Georges Mathé, MD, and their historic contributions to the world of oncology. Inspired by these...
Funding the Future of Cancer Research Led by Women Making an Impact
WOMEN WHO CONQUER CANCER (WWCC) funds the promising careers of the best and brightest women researchers through the Conquer Cancer Foundation’s Young Investigator Award (YIA) program. Thanks to the generosity of supporters, five awards were granted in 2017. Right now, gifts to the WWCC Endowment...
ASCO University Offers New Course Covering Resource-Stratified Guidelines
ASCO has created a series of clinical practice guidelines to benefit clinicians, public health leaders, and policymakers in all resource settings. These resource-stratified guidelines help medical professionals outline appropriate methods of treatment and care based on the level of health-care...
Effectiveness of Sentinel Lymph Node Biopsy in Patients With Newly Diagnosed Melanoma
Research presented at the 9th World Congress of Melanoma supports the updated guideline recommendation that sentinel lymph node biopsy be performed in more patients newly diagnosed with melanoma, as it has the potential to save lives due to the information the procedure provides. This biopsy can...
FDA Awards Grants for Clinical Trials to Stimulate Product Development for Rare Diseases
THE U.S. FOOD and Drug Administration (FDA) has awarded numerous new clinical trial research grants, totaling more than $22 million over the next 4 years, to boost the development of products for patients with rare diseases. These new grants were awarded to principal investigators from academia and ...
Carfilzomib May Be a Strong Candidate for Salvage Therapy in Relapsed/Refractory Multiple Myeloma—but Questions Remain
WITH THE INCLUSION of proteasome inhibitors and immunomodulatory agents first into salvage and then as components of first-line, consolidation, and maintenance regimens, response rates, depth of response, and median progression-free and overall survival have all improved for patients suffering...
Regional Radiation Therapy Reduces Risk of Regional Recurrence in Node-Positive Cutaneous Melanoma
IN A LARGE single-institution study reported in the Journal of the National Comprehensive Cancer Network, Tobin Strom, MD, and colleagues found that regional radiotherapy was associated with a reduced risk of regional recurrence in patients with node-positive cutaneous melanoma, including those...
No Progression-Free Survival Benefit With First-Line Nivolumab vs Chemotherapy in Advanced PD-L1–Positive NSCLC
AS REPORTED BY David P. Carbone, MD, PhD, of The Ohio State University Comprehensive Cancer Center, Columbus, and colleagues in The New England Journal of Medicine, the phase III CheckMate 026 trial has shown no progression-free survival benefit for first-line nivolumab (Opdivo) vs platinum-based...
For HPV Vaccine to Have Optimal Impact, ‘Provider Hesitancy’ Must Be Overcome
Honoring National Cancer Institute researchers Douglas R. Lowy, MD, and John T. Schiller, PhD, with the Lasker-DeBakey Clinical Medical Research Award for advances in technology that enabled the development of human papillomavirus (HPV) vaccines to prevent cervical cancer and other tumors caused by ...
ASCO Clinical Practice Guideline Update on Antiemetics in Patients With Cancer
AS REPORTED BY Paul J. Hesketh, MD, of Lahey Hospital and Medical Center, Burlington, Massachusetts, and colleagues in the Journal of Clinical Oncology, ASCO has updated its clinical practice guideline on the use of antiemetics in patients with cancer.1 The update was based on an expert panel...
Nivolumab/Ipilimumab in Patients With Advanced Melanoma Who Did or Did Not Discontinue Induction Treatment due to Adverse Events
IN A RETROSPECTIVE pooled analysis of the CheckMate 069 and 067 studies reported in the Journal of Clinical Oncology, Dirk Schadendorf, MD, of the University Hospital Essen and the German Cancer Consortium, and colleagues found little difference in the efficacy of combined nivolumab (Opdivo) and...
Nivolumab Treatment Beyond Disease Progression in Advanced Melanoma
In a retrospective analysis reported in JAMA Oncology, Georgina V. Long, MBBS, PhD, of the Melanoma Institute Australia, North Sydney, and colleagues found that a substantial proportion of patients with advanced melanoma derived benefit from continued nivolumab (Opdivo) treatment after Response...
Edward E. Partridge, MD, Named Chief Medical Officer of Guideway Care
Edward E. Partridge, MD, has been named Chief Medical Officer of the Birmingham, Alabama–based Guideway Care, according to an announcement by Craig Parker, the company’s President and Chief Executive Officer. Dr. Partridge, a gynecologic oncologist, is highly regarded for his work to improve...
Julie R. Palmer, ScD, Honored With 2017 AACR Distinguished Lecture on Cancer Health Disparities
The American Association for Cancer Research (AACR) awarded Julie R. Palmer, ScD, the AACR Distinguished Lecture on the Science of Cancer Health Disparities, funded by Susan G. Komen. Dr. Palmer was recognized for her work as a cancer epidemiologist who has devoted most of her career to...
FDA Conducts Global Operation to Protect Consumers From Potentially Dangerous Prescription Drugs Sold Online
THE U.S. FOOD AND DRUG ADMINISTRATION (FDA), in partnership with international regulatory and law enforcement agencies, recently took action against more than 500 websites that illegally sell potentially dangerous, unapproved versions of prescription medicines, including opioids, antibiotics, and...
Howard A. Fine, MD, Wins NIH Director’s Pioneer Award
Neuro-oncologist Howard A. Fine, MD, of Weill Cornell Medicine and NewYork-Presbyterian, will receive a 5-year, $6 million National Institutes of Health (NIH) Director’s Pioneer Award for brain cancer research. The award will support Dr. Fine’s approach to modeling deadly brain cancers in the...
Expert Point of View: Markus Joerger, MD, PhD, and Domenica Lorusso, MD, PhD
PRESS CONFERENCE MODERATOR Markus Joerger, MD, PhD, of St. Gallen Cancer Center, Switzerland, indicated that prior to the current study, it was unclear whether chemotherapy followed by surgery would be superior to chemoradiotherapy. “I think we all agree that it has been confirmed as the standard...
Breast Cancer Has Changed Me, But the Change Has Been Positive
I’ve always had dense breasts and avoided doing breast self-exams because I couldn’t tell if the lumpiness I was feeling was something serious or merely normal fibrous tissue. Instead I relied on my yearly mammogram to spot any early signs of cancer. Four years ago, I was once again relieved to...
